Early-Stage Cancer
Home » For Patient / Caregiver » Early-Stage Cancer

How precision oncology is improving care for patients with early-stage cancer

For patients with early-stage cancer, precision oncology can be used to tailor treatment based on a patient’s risk of recurrence by also looking at circulating tumor DNA (ctDNA) levels. Assessing ctDNA is in a patient’s blood after surgery helps doctors consider whether to deploy additional treatment options or tighter surveillance. This allows doctors to be more precise in personalizing the management of their patients with early-stage cancer.

Click the button below to find out more about testing for early-stage cancer.

Check out this one-minute Guardant Reveal™ launch video which gives you more information on the first blood-only test that is able to report within two weeks for residual and recurrent disease in two weeks, without the need for a tissue biopsy.

Hear from Dr. T. Raja, a leading medical oncologist from Apollo Cancer Centre in Chennai, India as he shares about using the Guardant Reveal™ test for the detection of minimal residual disease in patients with early-stage colorectal cancer.

Message us